NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”). The subscription price has been determined through an accelerated bookbuild transaction.
A number of Swedish and international institutional investors, including Tredje AP-fonden, Handelsbanken Fonder, Andra AP-fonden, Swedbank Robur Fonder, Fjärde AP-fonden and TIN Ny Teknik have subscribed for shares in the Issue. The Company believes that using the flexibility provided by a non-pre-emptive placing is the most appropriate transaction structure in order to raise capital in a time- and cost-effective manner, whilst also further diversifying and strengthening the Company’s shareholder base.
The Company intends to use the net proceeds from the Issue to:
“The interest in Xspray is extremely motivating and we would like to thank the investors for their confidence in Xspray and our R&D. With the additional capital, we now have the financial strength required for our business development negotiations with potential partners for our most advanced project HyNap-Dasa. It will also allow us to speed up development of the next-in-line product candidates in our pipeline. We plan to start the study program with HyNap-Nilo already in Q1 2021 and to bring the exciting but not yet communicated subsequent product candidates forward in development. Furthermore, we are now able to finalize the expansion of our production capability in Malta allowing us to work at full speed with several products simultaneously,“ says Per Andersson, CEO Xspray Pharma.
The Issue is expected to raise proceeds for the Company of SEK 265 million, before transaction costs. The Issue will result in an increase in the number of shares in Xspray of 1,861,291, from 17,031,213 to 18,892,504, and an increase in the share capital by SEK 1,861,291 from SEK 17,031,213 to 18,892,504 resulting in a dilution of approximately 10%.
In connection with the Issue, the Company has agreed to a lock-up undertaking on future share issuance for a period of 90 days, subject to customary exceptions. In addition, the management and Board of Directors have undertaken not to sell any shares in Xspray during the same period subject to the right to sell shares to cover tax liabilities and to exercise holdings in the Company’s incentive program and customary exceptions.
Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners are acting as Joint Bookrunners in connection with the Issue. Vinge is acting as legal advisor to the Company and Baker McKenzie is acting as legal advisor to Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners.